AstraZeneca (LON:AZN) Receives “Outperform” Rating from BMO Capital Markets

BMO Capital Markets restated their outperform rating on shares of AstraZeneca (LON:AZNFree Report) in a research note issued to investors on Monday morning, MarketBeat Ratings reports.

A number of other analysts also recently issued reports on the stock. Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a report on Thursday, February 8th. Citigroup reaffirmed a buy rating on shares of AstraZeneca in a research report on Tuesday, November 28th. JPMorgan Chase & Co. reiterated an overweight rating on shares of AstraZeneca in a research note on Friday, November 17th. Barclays restated a buy rating and issued a £135 ($170.50) price target on shares of AstraZeneca in a research note on Monday, November 20th. Finally, UBS Group cut their price objective on AstraZeneca from £107 ($135.14) to GBX 9,900 ($125.03) and set a sell rating for the company in a report on Monday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of £122.75 ($155.03).

View Our Latest Research Report on AZN

AstraZeneca Trading Up 1.4 %

AstraZeneca stock opened at GBX 9,637.63 ($121.72) on Monday. AstraZeneca has a one year low of GBX 9,461 ($119.49) and a one year high of £123.92 ($156.50). The business’s fifty day moving average is £104.56 and its 200 day moving average is £105.81. The stock has a market capitalization of £149.38 billion, a PE ratio of 3,146.03, a price-to-earnings-growth ratio of 0.47 and a beta of 0.19. The company has a debt-to-equity ratio of 75.70, a current ratio of 0.82 and a quick ratio of 0.59.

AstraZeneca Increases Dividend

The business also recently declared a dividend, which will be paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd will be issued a dividend of GBX 156 ($1.97) per share. This represents a yield of 1.49%. The ex-dividend date is Thursday, February 22nd. This is a positive change from AstraZeneca’s previous dividend of $71.80. AstraZeneca’s payout ratio is currently 7,549.67%.

Insider Transactions at AstraZeneca

In other news, insider Anna Manz bought 487 shares of AstraZeneca stock in a transaction that occurred on Tuesday, December 12th. The stock was bought at an average cost of £101.90 ($128.69) per share, with a total value of £49,625.30 ($62,674.03). In other news, insider Anna Manz bought 487 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were bought at an average price of £101.90 ($128.69) per share, for a total transaction of £49,625.30 ($62,674.03). Also, insider Michel Demare purchased 1,000 shares of the business’s stock in a transaction on Wednesday, November 22nd. The stock was acquired at an average price of £101.70 ($128.44) per share, with a total value of £101,700 ($128,441.53). Corporate insiders own 0.21% of the company’s stock.

About AstraZeneca

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Further Reading

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.